Apply suggestions from code review

commit agitter's changes

Co-authored-by: Anthony Gitter <agitter@users.noreply.github.com>

content/05.treat.md

@@ -180,19 +180,20 @@ However, in the long term, atomic convolutions may ultimately overtake grid-base
 
 #### *De novo* drug design
 
-*De novo* drug design attempts to model the typical design-synthesize-test cycle of drug discovery in-silico [@doi:10.1002/wcms.49; @doi:10.1021/acs.jmedchem.5b01849].
+*De novo* drug design attempts to model the typical design-synthesize-test cycle of drug discovery *in silico* [@doi:10.1002/wcms.49; @doi:10.1021/acs.jmedchem.5b01849].
 It explores an estimated 10<sup>60</sup> synthesizable organic molecules with drug-like properties without explicit enumeration [@doi:10.1002/wcms.1104].
-To score molecules after generation or during optimization, physics-based simulation could be used [@tag:Sumita2018], but machine learning models based on techniques discussed earlier may be preferable [@tag:Gomezb2016_automatic], as they are much more computationally expedient. Computationally efficiency is particularly important during optimization as the "scoring function" may need to be called thousands of times.
+To score molecules after generation or during optimization, physics-based simulation could be used [@tag:Sumita2018], but machine learning models based on techniques discussed earlier may be preferable [@tag:Gomezb2016_automatic], as they are much more computationally expedient.
+Computational efficiency is particularly important during optimization as the "scoring function" may need to be called thousands of times.
 
 To "design" and "synthesize", traditional *de novo* design software relied on classical optimizers such as genetic algorithms.
 These approaches can lead to overfit, "weird" molecules, which are difficult to synthesize in the lab.
-A popular approach which may help ensure synthesizability is to use rule-based virtual chemical reactions to generate molecular structures [@doi:10.1021/acs.jmedchem.5b01849].
+A popular approach that may help ensure synthesizability is to use rule-based virtual chemical reactions to generate molecular structures [@doi:10.1021/acs.jmedchem.5b01849].
 Deep learning models that generate realistic, synthesizable molecules have been proposed as an alternative.
 In contrast to the classical, symbolic approaches, generative models learned from data would not depend on laboriously encoded expert knowledge.
 
-In the past few years a large number of techniques for the generative modeling and optimization of molecules with deep learning have been explored, including recursive neural networks, variational autoencoders, generative adversarial networks, and reinforcement learning -- for a review see Elton, et al.[@tag:Elton_molecular_design_review] or Vamathevan et al.[@tag:Vamathevan2019].
+In the past few years, a large number of techniques for the generative modeling and optimization of molecules with deep learning have been explored, including RNNs, VAEs, GANs, and reinforcement learning -- for a review see Elton et al. [@tag:Elton_molecular_design_review] or Vamathevan et al [@tag:Vamathevan2019].
 
-Building off the large amount of work that has already gone into text generation,[@arxiv:1308.0850] many generative neural networks for drug design represent chemicals with the simplified molecular-input line-entry system (SMILES), a standard string-based representation with characters that represent atoms, bonds, and rings [@tag:Segler2017_drug_design].
+Building off the large amount of work that has already gone into text generation [@arxiv:1308.0850], many generative neural networks for drug design initially represented chemicals with the simplified molecular-input line-entry system (SMILES), a standard string-based representation with characters that represent atoms, bonds, and rings [@tag:Segler2017_drug_design].
 
 The first successful demonstration of a deep learning based approach for molecular optimization occurred in 2016 with the development of a SMILES-to-SMILES autoencoder capable of learning a continuous latent feature space for molecules[@tag:Gomezb2016_automatic].
 In this learned continuous space it is possible to interpolate between molecular structures in a manner that is not possible with discrete (e.g. bit vector or string) features or in symbolic, molecular graph space.
@@ -207,8 +208,8 @@ The initial RNN is then fine-tuned to generate molecules that are likely to be a
 Both the fine-tuning and reinforcement learning approaches can rediscover known, held-out active molecules.
 
 Reinforcement learning approaches where operations are performed directly on the molecular graph bypass the need to learn the details of SMILES syntax, allowing the model to focus purely on chemistry.
-Additionally, they seem to require less training data and generate more valid molecules since they are constrained by design only to graph operations which satisfy chemical valiance rules.[@tag:Elton_molecular_design_review]
-A reinforcement learning agent developed by Zhou et al. demonstrated superior molecular optimization performance on certain easy to compute metrics when compared with other deep learning based approaches such as the Junction Tree VAE, Objective Reinforced Generative Adversarial Network, and Graph Convolutional Policy Network [@doi:10.1038/s41598-019-47148-x].
+Additionally, they seem to require less training data and generate more valid molecules since they are constrained by design only to graph operations which satisfy chemical valiance rules [@tag:Elton_molecular_design_review].
+A reinforcement learning agent developed by Zhou et al. [@doi:10.1038/s41598-019-47148-x] demonstrated superior molecular optimization performance on certain easy to compute metrics when compared with other deep learning based approaches such as the Junction Tree VAE [add ref], Objective-Reinforced Generative Adversarial Network [add ref], and Graph Convolutional Policy Network [add ref].
 As another example, Zhavoronkov et al. used generative tensorial reinforcement learning to discover potent inhibitors of discoidin domain receptor 1 (DDR1) [@tag:Zhavoronkov2019_drugs].
 Their work is unique in that six lead candidates discovered using their approach were synthesized and tested in the lab, with 4/6 achieving some degree of binding to DDR1 [@tag:Zhavoronkov2019_drugs].